Blood Purification Center, Qingdao Municipal Hospital, Qingdao, China.
Health Management Center, Qingdao Municipal Hospital, Qingdao, China.
Cancer Biother Radiopharm. 2021 Nov;36(9):793-802. doi: 10.1089/cbr.2020.3608. Epub 2020 Jul 17.
Colorectal cancer (CRC), a malignant tumor, has become a highly relevant social problem. Nuclear paraspeckle assembly transcript 1 () was reported as an oncogenic long noncoding RNA in diverse tumors, including CRC. Nevertheless, the mechanism of in CRC remains unknown. The expression levels of and solute carrier family 38 member 1 () in CRC tissues and cells were detected by real-time quantitative polymerase chain reaction. The protein levels of p62, microtubule-associated protein light (LC3-I), LC3-II, and were examined by Western blot assay. Cell proliferation, apoptosis, and invasion were measured by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT), and flow cytometry and transwell assays, respectively. The interaction between miR-138 and or was predicted by StarBase or TargetScan, and verified by the dual-luciferase reporter assay. The effect of on tumor growth was determined in CRC mice model. The expression of and was upregulated in CRC tissues and cells. knockdown or downregulation restrained cell proliferation and invasion, and accelerated cell apoptosis and autophagy of CRC cells. acted as a sponge of miR-138 to regulate expression. Furthermore, deficiency suppressed tumor growth These studies disclosed that knockdown inhibited CRC progression by miR-138/ axis, providing an underlying target for CRC treatment.
结直肠癌(CRC)是一种恶性肿瘤,已成为一个高度相关的社会问题。核小体组装转录本 1()被报道为多种肿瘤中的致癌长非编码 RNA,包括 CRC。然而,在 CRC 中 的机制尚不清楚。通过实时定量聚合酶链反应检测 CRC 组织和细胞中 的表达水平。通过 Western blot 检测 p62、微管相关蛋白轻链 1(LC3-I)、LC3-II 和 的蛋白水平。通过 3-(4,5-二甲基-2-噻唑基)-2,5-二苯基-2-H-四唑溴盐(MTT)、流式细胞术和 Transwell 测定分别测量细胞增殖、凋亡和侵袭。StarBase 或 TargetScan 预测 miR-138 与 或 之间的相互作用,并通过双荧光素酶报告基因检测验证。在 CRC 小鼠模型中确定 对肿瘤生长的影响。 在 CRC 组织和细胞中上调了 和 的表达。 敲低或 下调抑制 CRC 细胞的增殖和侵袭,加速细胞凋亡和自噬。 作为 miR-138 的海绵调节 表达。此外, 缺陷抑制了肿瘤生长。这些研究表明, 通过 miR-138/ 轴抑制 CRC 进展,为 CRC 治疗提供了一个潜在的靶点。